NIH PA · NIH · R43, R44
PA-27-100: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The Small Business Innovation Research (SBIR) program helps United States small business concerns (SBCs) bring scientific innovations to the marketplace. The SBIR program supports feasibility studies to later research and development (R&D) needed to develop a commercial product.
- NOFO number
- PA-27-100
- Type
- PA
- Activity code
- R43R44
- Primary institute
- NIH
- Clinical trials
- Optional
- Posted
- May 28, 2026
- Opens
- Aug 5, 2026
- Expires
- Apr 6, 2027
PA-27-100 due dates
2 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| September 05, 2026 * | September 05, 2026 * | Not Applicable | November 2026 | January 2027 | April 2027 |
| January 05, 2027 * | January 05, 2027 * | Not Applicable | March 2027 | May 2027 | July 2027 |
| April 05, 2027 * | April 05, 2027 * | Not Applicable | July 2027 | August 2027 | December 2027 |
What its predecessor PA-24-245 funded
PA-27-100 reissues PA-24-245. Until awards appear under the new number, its funding history is the best guide to who wins under this program: 789 projects and $650.9M in FY2022–FY2026.
Projects funded
789
Distinct projects, FY2022–FY2026
New awards
674
Type 1 (new project) award records
NIH funding
$650.9M
Award dollars under PA-24-245, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 359 | 303 | $234.1M |
| FY2026 | 595 | 371 | $416.9M |
Institutions with the most funding
- Mucommune, LLC$11.6M · 8 projects
- Innovative Design Labs, Inc.$7.8M · 5 projects
- Epicypher, Inc.$6.7M · 4 projects
- Gentibio, Inc.$4.7M · 4 projects
- Hesperos, Inc$4.7M · 3 projects
- Trethera Corporation$4.7M · 3 projects
- Ridgeline Therapeutics, Inc.$4.4M · 2 projects
- Panluminate Inc.$4.0M · 5 projects
Funding institutes
- NCI$110.8M · 156
- NIGMS$86.0M · 127
- NIAID$73.2M · 126
- NHLBI$55.2M · 84
- NIDDK$52.8M · 77
- NINDS$48.8M · 51
- NIA$36.2M · 42
- NICHD$23.9M · 34
Activity codes funded
- R44507 records
- R43441 records
- R415 records
- U431 record
Most recent new awards
- Use of an Innovative Pre-Formed Structural Scaffold for Reconstruction of Segmental Bone Loss in a Zygomaticomaxillary Complex Model (opens NIH RePORTER)
Revbio, Inc. · 1R44DE035431-01 · NIDCR · Notice Sep 23, 2026
$1.3MR44
- The Therapeutic Development of a Clinical NR1H3 Antisense Oligonucleotide to Reprogram Microglia into a Neuroprotective State in ALS and FTD (opens NIH RePORTER)
Modulo Bio, Inc. · 1R44NS143633-01A1 · NINDS · Notice Sep 19, 2026
$848KR44
- Phase 2: Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus (opens NIH RePORTER)
Atticus Pharma Inc · 1R44AR087266-01A1 · NIAMS · Notice Sep 19, 2026
$1.0MR44
- Development of OPGx-RDH12 as a gene therapy for RDH12 deficiency associated Leber congenital amaurosis (LCA) (opens NIH RePORTER)
Opus Genetics Inc. · 1R44EY038152-01A1 · NEI · Notice Sep 19, 2026
$1.0MR44
- Rib Fixation for Prevention of Proximal Junctional Kyphosis (PJK) in Adult Spinal Deformity Surgery (opens NIH RePORTER)
Apex Orthopaedic Technologies LLC · 1R43AR085492-01A1 · NIAMS · Notice Sep 19, 2026
$316KR43
- PRMT5 Inhibitors as a Novel Therapy for Anti-VEGF-Sensitive and -Resistant Neovascular Age-Related Macular Degeneration (opens NIH RePORTER)
Eqon Pharmaceuticals, LLC · 1R43EY038150-01A1 · NEI · Notice Sep 18, 2026
$233KR43
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
36 NIH institutes and offices take applications under PA-27-100. Contact the program officer at the institute that fits your research before applying.
- NIH
- NEI · National Eye Institute
- NHLBI · National Heart, Lung, and Blood Institute
- NHGRI · National Human Genome Research Institute
- NIA · National Institute on Aging
- NIAAA · National Institute on Alcohol Abuse and Alcoholism
- NIAID · National Institute of Allergy and Infectious Diseases
- NIAMS · National Institute of Arthritis and Musculoskeletal and Skin Diseases
- NIBIB · National Institute of Biomedical Imaging and Bioengineering
- NICHD · Eunice Kennedy Shriver National Institute of Child Health and Human Development
- NIDCD · National Institute on Deafness and Other Communication Disorders
- NIDCR · National Institute of Dental and Craniofacial Research
- NIDDK · National Institute of Diabetes and Digestive and Kidney Diseases
- NIDA · National Institute on Drug Abuse
- NIEHS · National Institute of Environmental Health Sciences
- NIGMS · National Institute of General Medical Sciences
- NIMH · National Institute of Mental Health
- NINDS · National Institute of Neurological Disorders and Stroke
- NINR · National Institute of Nursing Research
- NIMHD · National Institute on Minority Health and Health Disparities
- NLM · National Library of Medicine
- NCCIH · National Center for Complementary and Integrative Health
- NCATS · National Center for Advancing Translational Sciences
- ORIP
- NCI · National Cancer Institute
- ORWH
- CDC
- FDA
- GH
- CCDPH
- NCEH
- IP
- CK
- PS
- NCBDD
- NCIPC
Related notices
NIH lists no related notices for PA-27-100 yet.
Award terms
- Application types allowed
- New Direct Phase II, Fast-Track, Phase I) Renewal Phase II) Resubmission Direct Phase II, Fast-Track, Phase I, Phase II) Revision Direct Phase II, Fast-Track, Phase I, Phase II) The OER Glossary and the How to Apply – Application Guide provide details on these application types. Only those application types listed here are allowed for the NOFO.
- Award budget
- Total funding support direct costs, indirect costs, fee) normally may not exceed the current SBA budgetary guidelines. For specific topics, NIH and CDC may exceed these total award amounts. For approved waiver topics, see Small Business Funding Considerations and Contacts. Budget guidelines can vary by participating component. Total funding support provided by NIH participating components…
- Project period
- According to statutory guidelines, award periods normally may not exceed 6 months for Phase I and 2 years for Phase II. Applicants are encouraged to propose a project duration period that is reasonable and appropriate for completion of the research project. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PA-24-245.
- Companion NOFOs: PA-27-101, PA-27-102, PAR-27-098.
Other open NOFOs for R43, R44
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.